Researchers have found positive results in the first human trials of a new vaccine candidate that works even if the virus mutates.
Scientists in Britain and Europe are poised to recruit thousands of people for large-scale trials which they hope will lead to widespread availability of the injection by 2018.
"This vaccine has the potential to save thousands of lives a year. Everyone working on it is wildly enthusiastic about the first positive results from small human trials," said Professor John Oxford, Britain's leading expert on flu and the study's key researcher.
Flu is one of the biggest global killers, causing up to 500,000 deaths every year. The threat is more when it mutates from a strain that attacks animals, particularly birds, and infects humans.
Current patients are given annual vaccines to protect them against most forms of influenza. But the jabs attack proteins known as H and N on the outside or "coat" of the virus.
These proteins are changeable and when they alter the vaccine is likely to become ineffective.
The aim of the universal jab is to overcome this by attacking parts of the virus that do not change, researchers said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
